| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Bevacizumab (Avastin) (CP.PHAR.93) - RETIRED (Medicare February 15, 2024) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Diagnostic Testing Guidelines for 2019-Novel Coronavirus (CP.MP.183) - RETIRED (Medicare February 15, 2024) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | DNA Analysis of Stool (CP.MP.125) - RETIRED (Medicare February 15, 2024) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Hyperemesis Gravidarum Treatment (CP.MP.34) - RETIRED (Medicare February 15, 2024) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Testing for Select GU Conditions | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Selective Dorsal Rhizotomy (CP.MP.174) (RETIRED - Medicaid January 17, 2024) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Casirivimab and imdevimab (REGN-COV2) (RETIRED Medicaid and Ambetter June 1, 2023) (CP.PHAR.520) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Bamlanivimab-etesevimab (LY-CoV555-LY-CoV016) (CP.PHAR.532) (RETIRED Medicaid and Ambetter June 1, 2023) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Incontinence Supplies (TX.CP.MP.508) (RETIRED Medicaid June 1, 2023) | |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Radiofrequency ablation of uterine fibroids | |